StreetAlpha.app
Home › Stocks › AKTS

Aktis Oncology, Inc. (AKTS)

$16.15
▼ −1.52%
LAST CLOSE · NOV 20

Aktis Oncology develops radiopharmaceutical cancer treatments that deliver radioactive material directly to tumors. It last closed at $16.15 on Nov 20, down 1.52% on the day. The next earnings report for AKTS is expected around Mon, Mar 29, 2027, after the close. Over its last 4 reports the stock moved an average of 6.4% the session after earnings. Over the last 12 months AKTS insiders bought $114.3M of stock on the open market and sold $3.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is AKTS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AKTS.
Next report
Mar 29
Estimated date · After the close
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How AKTS moved after its last 4 reports
Average move the session after a report ±6.4%
Nov 12, 2026Time not announced−4.5%
Aug 13, 2026After the close+4.8%
May 11, 2026After the close+8.0%
Mar 30, 2026After the close+8.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AKTSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AKTS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AKTS

Technical Analysis

AKTS · as of the Nov 20 close · updated each morning
Downtrend

The stock sits between its 20 and 50 day averages. It is 28% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the 20 day average at $16.10, and the nearest resistance the Pivot at $16.29.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.1%/day
Key levels
$34.1952 week high+111.7%
$21.38100 day average+32.4%
$20.67200 day average+28.0%
$17.7050 day average+9.6%
$16.78Swing high (Oct 22)+3.9%
$16.59Pivot R1+2.7%
$16.29Pivot+0.9%
$16.15Last close
$16.1020 day average−0.3%
$15.85Pivot S1−1.9%
$15.60Swing low (Nov 17)−3.4%
$13.9652 week low−13.6%
Indicators
RSI (14)45.92Middle of its rangeNeutral
MACD-0.35Above its signal lineBullish
Stochastic55.9Middle of its rangeNeutral
ADX (14)19.4No clear trend
Williams %R-49.4Oversold below −80, overbought above −20Neutral
CCI (20)22.5Oversold below −100, overbought above 100Neutral
Rate of change+2.1%Change over 10 sessionsBullish
ATR (14)$0.98Typical daily range, 6.0% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for AKTS

What happened before

See how AKTS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for AKTSHow many large options trades hit AKTS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AKTS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲84 buying vs 41 selling
  • ▲Shares held by funds +7.8%
  • ▲Funds holding +11
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding125114+9.6%
In funds' top 10550.0%
Held by funds–––
New / increased30 / 5451 / 27+7.7%
Reduced / sold out23 / 1818 / 6+70.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AKTS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AKTS Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$114.3M6 buys · 6 insiders
Sold$3.2M5 sales · 3 insiders
8% of the selling was under pre-arranged trading plans.
Cluster buy: 6 insiders bought $114.3M between Jan 12 and Jan 12.
2026-01 bought $114.3M2026-07 sold $3.0M2026-09 sold $259KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 23Akos CzibereChief Medical OfficerSale plan12,500$20.69$259K
Jul 20Ken HerrmannDirectorSale4,856$24.56$119K
Jul 17Ken HerrmannDirectorSale3,065$25.21$77K
Jul 8Akos CzibereChief Medical OfficerSale50,000$27.77$1.4M
Jul 8Shulamit Ron-BiggerCOOSale50,000$27.75$1.4M
Jan 12Ansbert Gadicke10% ownerBuy1,112,777$18.00$20.0M
Every insider buy and sale for AKTS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AKTS insider trades →

From SEC Form 4 filings by AKTS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AKTS is in one of them and how their past AKTS trades turned out.

AKTS in the AI portfolios
Loading…

AKTS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AKTS in an article yet. Here's the latest on the wider market.

AKTS in the news

About Aktis Oncology

Aktis Oncology is a company based in Boston that develops radiopharmaceuticals, which are cancer treatments that carry radioactive material directly to tumors. Its main focus is a platform built on small engineered proteins that bind to targets on cancer cells. Its lead candidate targets Nectin-4, a protein found on several solid tumor types, and is being tested in clinical trials for urothelial cancer and other tumors. The company works with isotope suppliers and contract manufacturers to supply these treatments to cancer patients and their doctors.

Headquarters
Boston, MA